Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ambit Biosciences, a private biopharmaceutical firm focusing on central nervous system disorders and cancer, has entered into screening collaborations with GlaxoSmithKline, Bristol-Myers Squibb and Pfizer to assist drug discovery and development efforts.
Subscribe to our email newsletter
Under the GSK collaboration, Ambit will employ its proprietary kinase platform to profile kinase target specificity of selected GSK compounds, thereby accelerating the discovery and development of novel drug candidates.
Under the Bristol-Myers Squibb collaboration, Ambit will employ its proprietary kinase platform to characterize the specificity of certain Bristol-Myers Squibb compounds.
Under the Pfizer collaboration, Ambit will employ its proprietary “reverse screening” technology to identify and characterize the protein targets of certain Pfizer drug discovery compounds and thereby elucidate their molecular mechanism of action.
Commenting on the company’s collaborations, Scott Salka, CEO of Ambit, said, “The earnings generated from our partnerships, including our existing multi-year collaboration with Roche, will support the continued development of Ambit’s pipeline of drug candidates for the treatment of stroke and various cancers, the first of which we plan to advance into clinical trials during 2005.”